Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 6, 2018

Primary Completion Date

December 13, 2022

Study Completion Date

December 13, 2022

Conditions
Recurrent or Metastatic Breast Cancer
Interventions
DRUG

DHP107

DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days

DRUG

IV Paclitaxel

IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)

Trial Locations (15)

15232

University of Pittsburgh Medical Center (UPMC), Pittsburgh

21401

Anne Arundel Health System Research Institute (AAHS), Annapolis

33486

Boca Raton Regional Hospital (BRRH), Boca Raton

34607

ASCLEPES Research Center(ARC), Weeki Wachee

48334

Michigan Center of Medical Research(MCMR), Farmington Hills

55426

Metro-Minnesota Community Oncology Research Consortium (MMCORC), Minneapolis

64111

Saint Luke's Cancer Institute(SLCI), Kansas City

66160

University of Kansas Medical Center(KUMC), Kansas City

89106

Nevada Cancer Research Foundation (NCRF), Las Vegas

90027

California Research Institute (CRI), Los Angeles

94115

University of California San Francisco (UCSF), San Francisco

02114

Massachusetts General Hospital(MGH), Boston

775 20

Onkologicka klinika, Fakultni nemocnice Olomouc (OUH), Olomouc

1106268 31

Onkologicky stacionar, NH Hospital a.s., nemocnice Horovice (NHH), Hořovice

128 08

Onkologicka klinika, Vseobecna fakultni nemocnice v Praze (VFN), Prague

All Listed Sponsors
lead

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

NCT03326102 - Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter